Skip to main content
Clinical Trials/NCT02005731
NCT02005731
Completed
N/A

A Prospective Multicenter Pilot Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction

Initia4 sites in 4 countries58 target enrollmentNovember 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Vasculogenic Erectile Dysfunction
Sponsor
Initia
Enrollment
58
Locations
4
Primary Endpoint
Change from baseline in the IIEF-EF (International Index of Erectile Function- Erectile Function Domain) score at 1, 3 and 6 months post treatment
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This is a prospective, pilot study for assessing the safety and efficacy of the treatments performed with Renova (LI-ESWT) on symptomatic ED patients.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
November 2013
Last Updated
11 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Initia
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Good general health
  • Vasculogenic ED for at least 6 months
  • International Index of Erectile Function 6 (IIEF-EF) between 11 to 25
  • Positive response to PDE5-I (able to penetrate on demand, Responders)
  • Negative response to PDE5-I (unable to penetrate on demand even with maximum PDE5-I dosage,Non-responders)
  • Stable heterosexual relationship for more than 3 months

Exclusion Criteria

  • Psychogenic ED
  • Neurological pathology
  • Hormonal pathology
  • Past radical prostatectomy
  • Recovering from cancer during last 5 years
  • Any unstable medical, psychiatric, spinal cord injury and penile anatomical - abnormalities
  • Clinically significant chronic hematological disease
  • Anti-androgens, oral or injectable androgens
  • Radiotherapy in pelvic region

Outcomes

Primary Outcomes

Change from baseline in the IIEF-EF (International Index of Erectile Function- Erectile Function Domain) score at 1, 3 and 6 months post treatment

Time Frame: 1, 3 and 6 months post treatment

Secondary Outcomes

  • Responses to the GAQ (Global Assessment questions) Questions 1 and 2 at 1, 3 and 6 months post treatment(1, 3 and 6 months post treatment)
  • Change from baseline in the SEP (Sexual Encounter Profile) Questions 2 and 3 at 1, 3 and 6 months post treatment(1, 3 and 6 months post treatment)

Study Sites (4)

Loading locations...

Similar Trials